A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.

被引：5
|
作者：
Motzer, Robert J.
Grunwald, Viktor
Hutson, Thomas E.
Porta, Camillo
Powles, Thomas
Eto, Masatoshi
Dutcus, Corina E.
Baig, Mahadi Ali
Dutta, Lea
Li, Di
Choueiri, Toni K.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Hannover Med Sch, Niedersachsen, Germany
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy
[5] Barts Hlth NHS Trust St Bartholomews Hosp, London, England
[6] Kyushu Univ, Fukuoka, Japan
[7] Eisai Inc, Woodcliff Lake, NJ USA
[8] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.TPS706
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS706
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subject with unresectable hepatocellular carcinoma.
    Finn, Richard S.
    Cheng, Ann-Lii
    Ikeda, Kenji
    Kudo, Masatoshi
    Tamai, Toshiyuki
    Dutcus, Corina E.
    Younger, Steven
    Han, Kwang-Hyub
    Qin, Shukui
    Raymond, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ)
    Schostak, Martin
    de Geeter, Patrick
    Decker, Thomas
    Resch, Anna
    Quiering, Claudia
    Schmitz, Stephan
    UROLOGIA INTERNATIONALIS, 2020, 104 (3-4) : 263 - 268
  • [23] Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan
    Hara, Takuto
    Suzuki, Kotaro
    Okamura, Yasuyoshi
    Chiba, Koji
    Sato, Ryo
    Matsushita, Yuto
    Tamura, Keita
    Ishikawa, Gaku
    Otsuka, Atsushi
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (12) : 1931 - 1936
  • [24] Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.
    Bracarda, Sergio
    Bamias, Aristotelis
    Casper, Jochen
    Negrier, Sylvie
    Sella, Avishay
    Staehler, Michael D.
    Tarazi, Jamal Christo
    Felici, Alessandra
    Rosbrook, Brad
    Jardinaud-Lopez, Monica
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [25] Editorial Comment on "Efficacy of pembrolizumab plus lenvatinib as first-line treatment for metastatic renal cell carcinoma with multiple brain metastases"
    Kato, Manabu
    IJU CASE REPORTS, 2025, 8 (01) : 9 - 10
  • [26] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Choueiri, T.
    Larkin, J.
    Albiges, L.
    Haanen, J. B.
    Schmidinger, M.
    Atkins, M. B.
    Mariani, M.
    Shnaidman, M.
    Di Pietro, A.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial
    Bjarnason, Georg A.
    Knox, Jennifer J.
    Kollmannsberger, Christian K.
    Soulieres, Denis
    Ernst, D. Scott
    Zalewski, Pawel
    Canil, Christina M.
    Winquist, Eric
    Hotte, Sebastien J.
    North, Scott A.
    Heng, Daniel Yick Chin
    Macfarlane, Robyn Jane
    Venner, Peter M.
    Kapoor, Anil
    Hansen, Aaron R.
    Eigl, Bernhard J.
    Czaykowski, Piotr
    Boyd, Ben
    Wang, Lisa
    Basappa, Naveen S.
    EUROPEAN JOURNAL OF CANCER, 2019, 108 : 69 - 77
  • [28] First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Peng, Libo
    CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 417e1 - 417e10
  • [29] Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma
    Zheng, Huanrui
    Zhou, Jin
    Tong, Yao
    Zhang, Jinhua
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [30] Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Li, Siming
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Guo, Jun
    ONCOTARGET, 2016, 7 (19) : 27044 - 27054
12345